ALERS — Eurobio Scientific SA Share Price
0.000.00%
Last trade - 00:00- €244.20m
- €251.61m
- €130.00m
- 93
- 43
- 79
- 88
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 31.82% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.37 | ||
| Price to Tang. Book | 8.64 | ||
| Price to Free Cashflow | 12.24 | ||
| Price to Sales | 1.69 | ||
| EV to EBITDA | 9.8 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.4% | ||
| Return on Equity | 3.76% | ||
| Operating Margin | 7.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 59.07 | 188.86 | 184.71 | 152.61 | 130 | 138 | 151.1 | 20.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1803.16 | +1109.94 | -15.28 | -51.7 | -60.53 | -19.63 | +31.82 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.
Directors
- Jean-Michel Grandmougin CHM (60)
- Herve Duchesne de Lamotte DCE (64)
- Denis Fortier DCE (53)
- Patrick De Roquemaurel IND (63)
- Michel Picot IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 15th, 1997
- Public Since
- November 18th, 2005
- No. of Employees
- 329
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 10,026,847
- Address
- Les Ulis Cedex, LES ULIS, 91953
- Web
- https://www.eurobio-scientific.com/
- Phone
- +33 1169796480
- Auditors
- Ernst & Young Audit
Upcoming Events for ALERS
Half Year 2025 Eurobio Scientific SA Corporate Sales Release
Similar to ALERS
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Eurobio Scientific SA share price?
As of Today at 20:30 UTC, shares in Eurobio Scientific SA are trading at €24.36. This share price information is delayed by 15 minutes.
How has the Eurobio Scientific SA share price performed this year?
Shares in Eurobio Scientific SA last closed at €24.36 and the price had moved by +68.66% over the past 365 days. In terms of relative price strength the Eurobio Scientific SA share price has outperformed the FTSE Global All Cap Index by +64.44% over the past year.
What are the analyst and broker recommendations for Eurobio Scientific SA?
The overall consensus recommendation for Eurobio Scientific SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eurobio Scientific SA dividend yield?
Eurobio Scientific SA does not currently pay a dividend.
Does Eurobio Scientific SA pay a dividend?
Eurobio Scientific SA does not currently pay a dividend.
When does Eurobio Scientific SA next pay dividends?
Eurobio Scientific SA does not currently pay a dividend.
How do I buy Eurobio Scientific SA shares?
To buy shares in Eurobio Scientific SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eurobio Scientific SA?
As of the previous close price of €24.36, shares in Eurobio Scientific SA had a market capitalisation of €244.20m.
Where are Eurobio Scientific SA shares listed?
Here are the trading details for Eurobio Scientific SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALERS
What kind of share is Eurobio Scientific SA?
Based on an overall assessment of its quality, value and momentum Eurobio Scientific SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eurobio Scientific SA share price forecast for 2025?
The analyst consensus target price for shares in Eurobio Scientific SA is €30.00. That is 23.18% above the last closing price of €24.36.
Analysts covering Eurobio Scientific SA currently have a consensus Earnings Per Share (EPS) forecast of €0.88 for the next financial year.
Find out moreWhat is the trend in the Eurobio Scientific SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eurobio Scientific SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -5.91%.
As of the last closing price of €24.36, shares in Eurobio Scientific SA were trading -1.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eurobio Scientific SA PE Ratio?
The Eurobio Scientific SA PE ratio based on its reported earnings over the past 12 months is 21. The shares last closed at €24.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eurobio Scientific SA?
Eurobio Scientific SA's management team is headed by:
- Jean-Michel Grandmougin - CHM
- Herve Duchesne de Lamotte - DCE
- Denis Fortier - DCE
- Patrick De Roquemaurel - IND
- Michel Picot - IND